Lombard Odier Asset Management USA Corp Has $1.56 Million Holdings in Silence Therapeutics PLC Sponsored ADR $SLN

Lombard Odier Asset Management USA Corp cut its stake in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) by 86.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 255,901 shares of the company’s stock after selling 1,589,047 shares during the period. Lombard Odier Asset Management USA Corp’s holdings in Silence Therapeutics were worth $1,556,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Nantahala Capital Management LLC increased its holdings in shares of Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after buying an additional 500,000 shares in the last quarter. Cantor Fitzgerald L. P. increased its holdings in shares of Silence Therapeutics by 1.6% during the third quarter. Cantor Fitzgerald L. P. now owns 801,306 shares of the company’s stock worth $4,159,000 after buying an additional 12,267 shares in the last quarter. UBS Group AG increased its holdings in shares of Silence Therapeutics by 34.5% during the third quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after buying an additional 78,854 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Silence Therapeutics by 50.3% during the third quarter. Millennium Management LLC now owns 298,512 shares of the company’s stock worth $1,549,000 after buying an additional 99,865 shares in the last quarter. Finally, Boothbay Fund Management LLC increased its holdings in shares of Silence Therapeutics by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 279,637 shares of the company’s stock worth $1,451,000 after buying an additional 27,216 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $6.71 on Wednesday. Silence Therapeutics PLC Sponsored ADR has a fifty-two week low of $4.19 and a fifty-two week high of $8.40. The firm’s 50-day simple moving average is $6.74 and its 200 day simple moving average is $6.10. The stock has a market cap of $316.98 million, a price-to-earnings ratio of -4.22 and a beta of 1.48.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.14). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.The firm had revenue of $0.42 million for the quarter, compared to the consensus estimate of $1.26 million. On average, sell-side analysts predict that Silence Therapeutics PLC Sponsored ADR will post -0.95 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, March 2nd. Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Silence Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.